Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 230,042 | 221,349 | 237,113 | 255,203 | 265,876 |
| Receivables | 18,000 | N/A | 100 | N/A | N/A |
| TOTAL | $251,440 | $226,074 | $241,417 | $255,982 | $267,726 |
| Non-Current Assets | |||||
| PPE Net | 1,335 | 1,295 | 1,253 | 854 | 724 |
| Other Non-Current Assets | 2,476 | 2,593 | 791 | 894 | 993 |
| TOTAL | $3,811 | $3,888 | $2,044 | $1,748 | $1,717 |
| Total Assets | $255,251 | $229,962 | $243,461 | $257,730 | $269,443 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,645 | 2,811 | 1,372 | 3,008 | 2,149 |
| Accrued Expenses | 7,339 | 7,361 | 5,710 | 5,506 | 4,612 |
| TOTAL | $11,846 | $11,015 | $7,531 | $8,950 | $7,184 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 231 | 469 | 274 | 408 | 538 |
| TOTAL | $231 | $469 | $274 | $408 | $538 |
| Total Liabilities | $12,077 | $11,484 | $7,805 | $9,358 | $7,722 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 24,000 | 23,399 | 23,338 | 23,297 | 23,271 |
| Common Shares | 2 | 2 | 2 | 2 | 2 |
| Retained earnings | -123,755 | -116,815 | -96,518 | -80,896 | -65,011 |
| TOTAL | $243,174 | $218,478 | $235,656 | $248,372 | $261,721 |
| Total Liabilities And Equity | $255,251 | $229,962 | $243,461 | $257,730 | $269,443 |